Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2011 - 2025)

Rigel Pharmaceuticals' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $1.4 million for Q3 2025.

• In Q3 2025, Current Deferred Revenue changed 0.0% year-over-year to $1.4 million; the TTM figure through Sep 2025 stood at $1.4 million (changed 0.0% YoY), while the FY2024 annual figure was $1.4 million, changed 0.0% from the prior year.
• Current Deferred Revenue was $1.4 million for Q3 2025 at Rigel Pharmaceuticals, roughly flat from $1.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $9.5 million in Q1 2021 to a low of $1.4 million in Q2 2023.
• Historically, Current Deferred Revenue has averaged $2.2 million across 5 years, with a median of $1.4 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue surged 362.74% in 2021, then sank 77.93% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $2.6 million in 2021, then sank by 47.27% to $1.4 million in 2022, then decreased by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
• The last three Current Deferred Revenue figures came in at $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $1.4 million (Q1 2025), per Business Quant data.